| Bayer expects China approval for stroke drug Xarelto |
ReutersThe other two are Boehringer Ingelheim's Pradaxa, and Eliquis, developed by Bristol-Myers Squibb and Pfizer. Xarelto has already won approvals from the United States, European Union, Malaysia and Japan for use to prevent stroke in patients with atrial ...
|
| Delegate Wants To Ban Arsenic In Chicken Feed |
CBS LocalDelegate Tom Hucker, D-Montgomery, told a panel of his colleagues Wednesday that even though Pfizer Inc. has voluntarily suspended the sale of roxarsone, a chemical often put in chicken feed to help the birds grow and fight parasites, ...
|
| Healthcare Sector Review: Nestle Leads Round 2 in Pfizer Buy, Sangamo Q4 Report |
Wall St. Cheat SheetPfizer Inc. (NYSE:PFE): Nestle (NSRGY) emerged as the leader to buy Pfizer's (NYSE:PFE) $10B Wyeth infant nutrition business as it battles Danone (DANOY), reports Reuters. Mead Johnson (NYSE:MJN) and Heinz (NYSE:HNZ) are also involved in the second ...
|
| Delegate wants to ban arsenic in chicken feed |
ABC2 NewsDelegate Tom Hucker, D-Montgomery, told a panel of his colleagues Wednesday that even though Pfizer Inc. has voluntarily suspended the sale of roxarsone, a chemical often put in chicken feed to help the birds grow and fight parasites, ...
|
| Boehringer Ingelheim/Pfizer's Spiriva Has Earned Decision Resources ... |
EON: Enhanced Online News (press release)... based on clinical data and the opinions of interviewed thought leaders, Boehringer Ingelheim/Pfizer's Spiriva has earned Decision Resources' proprietary clinical gold standard status for the treatment of chronic obstructive pulmonary disease (COPD) ...
|
| Pfizer Selects Biologics, Inc. as Limited Distribution Network Partner (LDN) |
EON: Enhanced Online News (press release)CARY, NC--(EON: Enhanced Online News)--Biologics, Inc., an integrated oncology services company has been selected as a Limited Distribution Network (LDN) partner for Pfizer's Inlyta which was approved by the FDA on January 27, 2012.
|
| pSivida Corp. Reports Results for the Second Quarter Ended December 31, 2011 |
EON: Enhanced Online News (press release)The Company granted Pfizer an exclusive option under various circumstances to license the development and commercialization worldwide of this insert for human ophthalmic disease other than uveitis. “We are also pleased with the progress being made in ...
|
